Non-squamous cell carcinoma
Showing 1 - 25 of >10,000
Advanced Lung Squamous Cell Carcinoma
Not yet recruiting
- Advanced Lung Squamous Cell Carcinoma
- No treatment is included in this study
-
Changsha, Hunan, ChinaYongchang Zhang
Aug 11, 2023
Squamous Cell Cancer, Squamous Cell Carcinoma, Skin Cancer Trial in Boise (30% ascorbic acid in DMSO)
Recruiting
- Squamous Cell Cancer
- +3 more
- 30% ascorbic acid in DMSO
-
Boise, IdahoCenter for Biomedical Research,Inc.
Jul 2, 2023
Prognostic Immune Biomarkers in HNSCC
Completed
- Head and Neck Cancer
- Squamous Cell Carcinoma
- Tumour immunoprofile evaluation
-
Ostrava, Moravian-Silesian Region, CzechiaUniversity Hospital Ostrava
Jul 3, 2023
Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck, Tumors Trial in Melbourne
Not yet recruiting
- Cutaneous Squamous Cell Carcinoma
- +3 more
-
Melbourne, Victoria, AustraliaPeter MacCallum Cancer Centre
May 17, 2023
Oral Cavity Squamous Cell Carcinoma Trial in San Francisco (NisinZ® P, Surgery (non-interventional, standard of care))
Not yet recruiting
- Oral Cavity Squamous Cell Carcinoma
- NisinZ® P
- Surgery (non-interventional, standard of care)
-
San Francisco, CaliforniaUniversity of California, San Francisco
Oct 18, 2023
Non Squamous Non Small Cell Lung Cancer, EGFR Positive NSCLC Trial (Toripalimab plus Chemotherapy)
Not yet recruiting
- Non Squamous Non Small Cell Lung Cancer
- EGFR Positive Non-small Cell Lung Cancer
- Toripalimab plus Chemotherapy
- (no location specified)
Jul 28, 2023
Carcinoma, Squamous Cell of Head and Neck, NSCLC, Ovarian Tumors Trial (disitamab vedotin)
Not yet recruiting
- Carcinoma, Squamous Cell of Head and Neck
- +3 more
- disitamab vedotin
- (no location specified)
Aug 15, 2023
Esophageal Squamous Cell Carcinoma, Chemo Effect, Side Effect of Drug Trial in Nanjing (Consolidation chemo (4 courses),
Recruiting
- Esophageal Squamous Cell Carcinoma
- +2 more
- Consolidation chemotherapy (4 courses)
- Concurrent chemotherapy (2 courses)
-
Nanjing, Jiangsu, ChinaThe First Affiliated Hospital of Nanjing Medical University
Mar 16, 2023
NSCLC, Carcinoma, Renal Cell, Esophageal Squamous Cell Carcinoma Trial (QEQ278)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- +3 more
- QEQ278
- (no location specified)
Jul 14, 2022
Sinonasal Cancer, Squamous NSCLC, Lung Cancer Trial run by the National Cancer Institute (NCI) (pembrolizumab, valemetostat)
Not yet recruiting
- Sinonasal Cancer
- +5 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jun 5, 2023
PARP Inhibitor for Esophageal Squamous Cell Carcinoma Trial (Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only
Not yet recruiting
- PARP Inhibitor for Esophageal Squamous Cell Carcinoma
- Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm))
- (no location specified)
Sep 24, 2023
NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Cadonilimab
- +2 more
-
Wuhan, Hubei, ChinaQian Chu
Aug 18, 2023
The Long Non Coding MALAT1 asPotential Salivary Diagnostic
Completed
- Oral Cancer Biomarkers
-
Giza, EgyptRania Hassan Shalby
Jan 31, 2023
Head and Neck Squamous Cell Carcinoma Trial in Spain (Dostarlimab, Niraparib, cisplatin plus radiotherapy)
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- Dostarlimab
- +2 more
-
Badalona, Cataluña, Spain
- +4 more
Mar 13, 2023
NSCLC Trial in Chongqing (procedure, drug, radiation)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- bronchial artery interventional therapy
- +3 more
-
Chongqing, Chongqing, ChinaDaping Hospital, Third Military Medical University
May 27, 2023
Advanced or Metastatic Squamous NSCLC Trial in Sydney (HMBD-001, Docetaxel, Cetuximab)
Not yet recruiting
- Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
- HMBD-001
- +2 more
-
Sydney, New South Wales, AustraliaGenesisCare North Shore
Jun 20, 2023
Advanced Squamous Non Small Cell Lung Cancer Trial (AK112, Carboplatin, Paxlitaxel, Tislelizumab, Carboplatin, Paxlitaxel)
Not yet recruiting
- Advanced Squamous Non Small Cell Lung Cancer
- AK112, Carboplatin, Paxlitaxel
- Tislelizumab, Carboplatin, Paxlitaxel
- (no location specified)
Apr 21, 2023
Esophageal Squamous Cell Carcinoma, Esophagectomy, Radiotherapy Trial (Since the data were collected retrospectively, there were
Completed
- Esophageal Squamous Cell Carcinoma
- +3 more
- Since the data were collected retrospectively, there were no interventions
- (no location specified)
Oct 31, 2022
NSCLC Trial (Ivonescimab Injection, Pembrolizumab Injection)
Not yet recruiting
- Non-Small Cell Lung Cancer
- Ivonescimab Injection
- Pembrolizumab Injection
- (no location specified)
Jun 9, 2023
Head and Neck Squamous Cell Carcinoma Trial in Shanghai (Apatinib Mesylate Tablets, Tegafur Gimeracil Oteracil Potassium
Completed
- Head and Neck Squamous Cell Carcinoma
- Apatinib Mesylate Tablets
- Tegafur Gimeracil Oteracil Potassium Capsules
-
Shanghai, Shanghai, ChinaShanghai ninth people's hospital
Jul 20, 2022
Advanced Squamous Non-Small-Cell Lung Cancer Trial (Trilaciclib, Carboplatin, Paclitaxel)
Not yet recruiting
- Advanced Squamous Non-Small-Cell Lung Cancer
- Trilaciclib
- +3 more
- (no location specified)
Jun 11, 2023
NSCLC Trial in Wuhan (Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel)
Recruiting
- Non-small Cell Lung Cancer
- Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel
-
Wuhan, Hubei, ChinaUnion hospital
Feb 20, 2023